CET

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

Retrieved on: 
Friday, December 2, 2022

HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentations from the barzolvolimab development program will be presented at the 6th GA2LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6th.

Key Points: 
  • Presentations at GUF 2022 are outlined below and include new data from both the Phase 1b 1.5 mg/kg cohort conducted in cold urticaria and long term follow data from the Phase 1b 3.0 mg/kg cohorts conducted in cold urticaria and symptomatic dermographism.
  • The chronic spontaneous urticaria (CSU) and wound healing presentations are Encore presentations and do not include new data.
  • The event will be webcast live and can be accessed by going to the "Events & Presentations" page under the "Investors & Media section of the Celldex Therapeutics website at www.celldex.com .
  • Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.

EQS-News: GBC AG: Invitation to the 5th International Investment Forum (IIF) - [ONLINE] December 07, 2022

Retrieved on: 
Friday, December 2, 2022

GBC AG: Invitation to the 5th International Investment Forum (IIF) - [ONLINE] December 07, 2022

Key Points: 
  • GBC AG: Invitation to the 5th International Investment Forum (IIF) - [ONLINE] December 07, 2022
    The issuer is solely responsible for the content of this announcement.
  • we hereby invite you to attend the 5th International Investment Forum (IIF) on December 07, 2022 starting at 09:55 am (CET).
  • As a purely digital live event, the International Investment Forum (IIF) provides instant access to listed companies from around the world.
  • The companies offer unique insights into their business models and current corporate development and are available live to answer questions from all investors by chat.

Central Securities Corporation Announces Reinvestment Price of Shares for Distribution Payable December 22, 2022

Retrieved on: 
Thursday, December 1, 2022

Central Securities Corporation (NYSE American: CET) announced today that the price at which Common Stock will be issued in payment of the $2.25 per share distribution payable on December 22, 2022 is $35.36 per share.

Key Points: 
  • Central Securities Corporation (NYSE American: CET) announced today that the price at which Common Stock will be issued in payment of the $2.25 per share distribution payable on December 22, 2022 is $35.36 per share.
  • This price is the arithmetic average of the daily volume weighted average price (VWAP) of the Corporations Common Stock for each of the last three trading days ending on and including December 1, 2022, rounded to two decimal places.
  • The distribution was previously announced on November 3, 2022 and is payable to shareholders of record on November 14, 2022.
  • The final tax breakdown of all amounts paid during 2022 will be available after year end.

Stellantis CEO Carlos Tavares Delivers CES 2023 Keynote Address With Ram and Peugeot Unveiling New Concepts

Retrieved on: 
Thursday, December 1, 2022

CEO Carlos Tavares has been invited by CES, the worlds most influential tech event, to deliver a keynote address on Thursday, January 5, 2023 in the Venetian Palazzo Ballroom in Las Vegas.

Key Points: 
  • CEO Carlos Tavares has been invited by CES, the worlds most influential tech event, to deliver a keynote address on Thursday, January 5, 2023 in the Venetian Palazzo Ballroom in Las Vegas.
  • The keynote address includes the global unveils of the Ram 1500 Revolution Battery Electric Vehicle (BEV) Concept and the Peugeot Inception Concept.
  • The presentation will chronicle Stellantis vision of making mobility clean, safe and affordable for all.
  • The Stellantis keynote at CES 2023 is scheduled for 2 p.m. PST/5 p.m. EST/11 p.m. CET on January 5, 2023.

EQS-News: Allterco JSCo updates invitation and documents to Extraordinary General Meeting of Shareholders

Retrieved on: 
Thursday, December 1, 2022

Sofia / Munich, 1December 2022 Allterco JSCo (ticker A4L / ISIN: BG1100003166 ) ("Allterco"), a provider of IoT and smart home products based in Sofia, Bulgaria, has updated the invitation to the Extraordinary General Meeting of shareholders convened for 13 December 2022 at 10.00 CET / 11.00 EET in Sofia, Bulgaria.

Key Points: 
  • Sofia / Munich, 1December 2022 Allterco JSCo (ticker A4L / ISIN: BG1100003166 ) ("Allterco"), a provider of IoT and smart home products based in Sofia, Bulgaria, has updated the invitation to the Extraordinary General Meeting of shareholders convened for 13 December 2022 at 10.00 CET / 11.00 EET in Sofia, Bulgaria.
  • Further information can be found at: https://allterco.com/en/for-investors/general-meeting-of-the-shareholder...
    Allterco JSCo is a technology holding company that stands for innovation through the development, manufacture, and distribution of high-quality IoT products.
  • Allterco was founded in Bulgaria and works with a team of young, talented developers who are dedicated to producing competitive and user-friendly products.
  • The Group consists of 5 subsidiary companies and has offices in Bulgaria, China, USA and Germany.

BIOPHYTIS ORGANISES A WEBCAST WITH KEY OPINION LEADERS (KOL) ON THE PHASE 2-3 COVA STUDY RESULTS OF SARCONEOS (BIO101) IN THE TREATMENT OF PNEUMONIA IN COVID-19 PATIENTS AT RISK OF RESPIRAT

Retrieved on: 
Thursday, December 1, 2022

The regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations will start in 2023.

Key Points: 
  • The regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations will start in 2023.
  • As a reminder, the COVA clinical study (identifier clinicaltrials.gov: NCT04472728) is an international, multi-centre, double-blind, placebo-controlled, group-sequential and adaptive two-part study.
  • It is a phase 2-3 study evaluating Sarconeos (BIO101) in patients aged 45 years and older, hospitalised with severe respiratory manifestations of COVID-19.
  • Part 2 of the COVA study is a randomised phase 3 study investigating the safety and efficacy of Sarconeos (BIO101) on respiratory function in patients.

RetinAI launches Discovery CORE: an AI-powered, collaborative platform to accelerate Clinical and Academic Research, and RWE analysis in ophthalmology

Retrieved on: 
Thursday, December 1, 2022

Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and imaging datasets.

Key Points: 
  • Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and imaging datasets.
  • The software measures retinal fluid volumes and layer thickness across OCT datasets automatically in real time.
  • Caption: A look at the Discovery CORE platform and its AI.
  • RetinAI is excited to offer Discovery CORE and its AI as a free trial for the first 2 months for users signing up on the platform.

Invitation to presentation of Sectra's six-month interim report 2022/2023 and date for CMD 2023

Retrieved on: 
Thursday, December 1, 2022

Sectra will also hold a Capital Markets Day (CMD) on January 27, 2023.

Key Points: 
  • Sectra will also hold a Capital Markets Day (CMD) on January 27, 2023.
  • Publication of the financial report: 8:15 a.m. (CET) on December 16, 2022
    Participation will take place via Microsoft Teams.
  • Questions can be posed using the chat function or by sending questions in advance via email to [email protected] .
  • The CMD will be a hybrid event, with the possibility to attend in person or online.

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

Retrieved on: 
Wednesday, November 30, 2022

LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that an abstract highlighting updated interim results from the ongoing Phase I/IIa CHIRON and THETIS clinical trials evaluating clonal neoantigen-reactive T cells (cNeT) has been accepted for a poster presentation at the ESMO Immuno-Oncology Annual Congress (ESMO IO) taking place in Geneva, Switzerland from December 7-9, 2022. cNeT are the active component of the final, precision T cell product which target tumors through recognition of a patient’s clonal neoantigens present on all tumor cells.

Key Points: 
  • We believe this supports the potential for deep and durable clinical responses that can ultimately help extend overall survival, said Dr Karl Peggs, Chief Medical Officer of Achilles Therapeutics.
  • The encouraging safety and tolerability profile, coupled with reduced dose lymphodepletion and IL-2 continues to support expanded application to a broader patient population.
  • We look forward to sharing additional updated safety, activity, and translational science details at ESMO IO.
  • Safety and tolerability observations of cNeT compare favorably to standard tumor infiltrating lymphocytes (TIL) due to less IL-2 related toxicity.

Promontory Therapeutics to Present Research on PT-112 in Advanced Non-Small Cell Lung Cancer at the ESMO Immuno-Oncology Congress 2022

Retrieved on: 
Wednesday, November 30, 2022

Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.

Key Points: 
  • Abstracts will be published online on the ESMO website at 12:05 a.m. CET on Thursday, Dec. 1, 2022.
  • Abstracts will also be published online in the ESMO-IO Congress 2022 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).
  • PT-112 represents a highly potent inducer of this immunological form of cancer cell death.
  • Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy.